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Tissue-Specific Bioink from 
Xenogeneic Sources for 3D 
Bioprinting of Tissue Constructs
Sriya Yeleswarapu, Shibu Chameettachal, Ashis Kumar Bera 
and Falguni Pati
Abstract
3D bioprinting brings new aspirations to the tissue engineering and regenera-
tive medicine research community. However, despite its huge potential, its growth 
towards translation is severely impeded due to lack of suitable materials, technolog-
ical barrier, and appropriate validation models. Recently, the use of decellularized 
extracellular matrices (dECM) from animal sources is gaining attention as printable 
bioink as it can provide a microenvironment close to the native tissue. Hence, it 
is worth exploring the use of xenogeneic dECM and its translation potential for 
human application. However, extensive studies on immunogenicity, safety-related 
issues, and animal welfare-related ethics are yet to be streamlined. In addition, the 
regulatory concerns need to be addressed with utmost priority in order to expedite 
the use of xenogeneic dECM bioink for 3D bioprinted implantable tissues for 
human welfare.
Keywords: 3D bioprinting, xenogeneic tissues and organs, xenogeneic decellularized 
extracellular matrix (dECM), dECM bioink
1. Introduction
The field of tissue engineering centers on development of tissues that are 
capable to regenerate and has a capacity to restore the damaged organs both struc-
turally and functionally [1, 2]. Scaffolds that are developed to serve this purpose 
should be able to provide cell attachment sites and allow cell proliferation and 
migration while maintaining its structural and mechanical integrity [2]. Along with 
this, the placement and uniform distribution of cells in the scaffold play a major 
role to determine its functional efficiency [3]. This precise positioning of multiple 
cell types in an organized manner can be achieved with 3D bioprinting [4]. Plenty 
of natural materials, such as gelatin [5, 6], alginate [7–9], collagen [10, 11], and 
synthetic materials like polycaprolactone (PCL) [12–16] and polyethylene glycol 
(PEG) [17–22], come in handy while printing a structure. Although the above-
mentioned natural materials are biocompatible, disadvantages such as mechanical 
instability, limited degradability, restricted cell proliferation, and differentiation 
challenged researchers to investigate more on natural materials [23–25]. As a result, 
human organ/tissue specific extracellular matrix (ECM) emerged as a best source 
to develop a functional tissue in laboratory conditions [23, 26, 27]. Yet, the major 
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limitation for this best material is its availability [28–30]. The next alternative 
source of ECM is to use from other species that are anatomically, physiologically, 
and metabolically similar to the recipient such as nonhuman primates (like apes, 
monkeys, and porcine) [31–33]. However, due to the risk of infections from nonhu-
man primates to human patients and organs from apes, baboons are abandoned, 
and hence pig became a suitable candidate as an organ donor for humans [33]. 
There is growing interest of xenogeneic ECM material as printable bioink (biomate-
rial formulation used for bioprinting) in the field of bioprinting due to easy access 
and the availability in required quantity. A process termed decellularization allows 
maximum removal of cellular content while retaining the ECM components from 
the native animal tissue to reduce the chance of immune rejection when implanted 
in the patient [29]. The first ever reported in vivo study of decellularized tissue was 
reported in 1991 by Krejci et al. [34], where human decellularized skin was used 
in mouse model. In 1995, Badylak’s group used decellularized xenogeneic small 
intestinal submucosa for Achilles tendon repair [35]. Later, a number of decel-
lularized ECM (dECM)-based devices are introduced, e.g., human dermis, porcine 
urinary bladder, porcine small intestine submucosa, and porcine heart valves 
[36] (Figure 1; for details refer to Table 1). In the recent past, there are several 
preliminary reports demonstrating the use of animal-derived dECM in the form of 
bioinks for developing functional tissues [27, 37]. Not only high cellular viability, 
these dECM-based constructs also showed enhanced differentiation and prolifera-
tion of cells into specific cell types when embedded in tissue-specific ECM [23, 
27, 38]. Apart from the need to develop a fully functional construct, the foremost 
reason for not implanting these structures into human beings is due to high risk of 
xenotoxicity. Other species, being the source of material for the scaffold that has 
to be transplanted into human, have to undergo several stringent laws and clear all 
the clinical trials and ethical concerns. In this book chapter, discussion on the status 
of xeno-sourced dECM-based bioprinting, including the few reported preclinical 
studies, is included. The processing steps for dECM preparation and associated 
Figure 1. 
An upright triangle representing number of decellularied xeno-transplants that are being tested at various 
stages viz in vitro lab experiments, animal and human trials.
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Source Tissue Cell types Recipient Result Reference
Porcine Pericardium Human sheath 
synoviocyte, 
human adipose 
derived stem cells
In vitro 
culture
• Production od synovial 
fluid with hyaluronic 
acid
[126]
Porcine Myocardium Porcine adipose 
derived stem cells, 
rat adipose derived 
stem cells
Rat 
myocardial 
infarction 
model
• Stem cells expressed 
endothelial marker
• Increased vascular 
formation in the 
myocardial tissue
[127]
Porcine Myocardium Human embryonic 
stem cells
In vitro 
culture
• Myocardial maturation [128]
Porcine Liver Rat endothelial 
cells
In vitro, 
culture 
and in vivo 
porcine 
model
• Clinically relevant 
vascularized bioengi-
neered liver
[129]
Balb/c 
Mice
Liver Balb/c Mice 
derived 
mesenchymal  
stem cells
In vitro 
culture
• Maturation of hepatic 
like tissue
[130]
Rat Liver Adult rat 
hepatocyte
In vitro 
culture
• In vitro maturation 
of liver with albumin 
secretion, urea syn-
thesis and cytochrome 
P450 expression
[131]
Porcine Liver Second trimester 
human fetal liver 
cells-hepatocytes, 
stellate cells
In-vitro, 
culture 
and in vivo 
porcine 
model
• In vitro maturation 
of liver with albumin 
secretion, normal 
metabolic parameter
[132]
Rat Heart Rat neonatal 
cardiocytes, rat 
aortic endothelial 
cells
In vitro 
culture
• Increasing of left 
and right ventricular 
pressure
• Contraction after 8 
days of In vitro culture
[133]
Mice Heart Human induced 
pluripotent stem 
cell-derived 
multipotential 
cardiovascular 
progenitor cells
In vitro 
culture
• Engineered heart 
tissues exhibited spon-
taneous contractions, 
generated mechanical 
forces
• Drug responsive
[134]
Mice Lungs Mesenchymal 
Stromal cells 
derived from bone 
marrow of adult 
male mice
In vitro 
culture
• Matrix from decel-
lularized fibrotic lungs 
support prolonged 
growth of cells
• Decellularized lungs 
that are diseased can 
significantly affect 
the cell growth and 
differentiation
[135]
Porcine Kidney Immortalized 
murine 
hematopoietic 
support 
endothelial cell line
In vitro, 
culture 
and in vivo 
Yorkshire 
porcine
• Unseeded implanted 
scaffolds sustained 
blood pressure, 
renal ultrastructure 
maintained
[136]
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Source Tissue Cell types Recipient Result Reference
Porcine Kidney Mice embryonic 
stem cells
In vitro 
culture
• Reseeded scaffold 
showed HGF and 
VEGF levels  
similar to native  
kidney
[137]
Porcine Pancreas Human amniotic 
fluid derived stem 
cells
In vitro 
culture
• Acellular pancreas 
supported stem cell 
and pancreatic islets 
growth
• Could serve as a 
platform for bioengi-
neering pancreas to 
treat diabetes  
mellitus
[138]
Female 
ICR mice
Pancreas Acinar AR42J and 
beta MIN-6β cell 
lines
Mice model • Strong up-regulation 
of insulin gene
[139]
Rats Spinal cord Acellular scaffolds 
for in-vivo, 
NIH3T3 cells for 
in-vitro studies
In-vitro
culture 
and in vivo 
Sprague-
dawley 
Rats
• Induce the regenera-
tion of injured nerves 
(in vivo)
• Enhanced adhesion 
and proliferation of 
cells (in vitro)
[140]
Porcine Brain iPSC derived 
neural progenitor 
cells (NPCs)
In-vitro, 
culture 
and in vivo 
mice model
• NPC expressed 
neural markers in brain 
matrix gel (in vitro),
• Formation and 
assembling of larger 
microscale fibril 
like structure in gel 
(in-vivo)
[141]
Porcine Skin Human dermal 
fibroblasts
In-vitro 
culture 
• Gene ontology showed 
skin morphogenesis, 
epidermis development
[142]
Porcine Cornea Acellular Cornea In-vitro 
rabbits
• In-vivo good 
biocompatibility,
• Translucent cornea 
within 8 weeks
• Implants integrated 
into rabbit cornea 
without rejection  
signs
[143]
Porcine Cornea Rabbit corneal 
keratocytes, 
epithelial, 
endothelial
In vitro 
culture
• Epithelial cells showed 
high expressions of 
CK3, spindle shape 
keratocytes displayed 
vimentin
[144]
Porcine Cornea and 
limbus
Acellular scaffolds In vivo 
rabbit 
model
• Corneal transparency 
and epithelial integrity 
with no graft  
rejection
• Basal epithelial  
cell matured to limbal 
epithelial cells
[145]
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benefits in terms of immuno-compatibility, possible immunological reactions dur-
ing xenotransplantation, importance of xenografts, ethical concerns, and regula-
tory restrictions are also discussed.
2. Immunogenicity against dECM
Xenotransplantation may be the best way to alleviate the burden of allograft 
organ shortage from the last decade. The most enormous barrier to xenotransplan-
tation is the immunological rejection which de-emphasizes this technique. The 
profound immunological rejection happens by both antibody-mediated immune 
response as well as cell-mediated innate or adaptive immune response. Several car-
bohydrate antigens have been identified that could act as targets for human natural 
Source Tissue Cell types Recipient Result Reference
Porcine Myocardium 
Slice
Acellular patch Acute 
myocardial 
infarction 
rat model
• Firm attachment and 
integration with the 
infarcted region
• Neovascularization 
within 1 week, 
contraction of left 
ventricle wall and 
cardiac functional 
parameters improved 
significantly
[146]
Porcine Liver Hepatoblastoma 
(HepG2)
In-vivo 
rodent 
model
• Intact liver capsule 
with porous acel-
lular lattice structure 
with cell supportive 
behaviour
• No immunogenicity 
observed
[147]
Porcine Heart valves 
(SynergraftTM)
Acellular scaffolds Human 
study 
4 male 
children
• 3 Children died of 
graft rupture
• Severe inflammation
• Significant calcific 
deposits
• No cell repopulation of 
porcine matrix
[56]
Bovine Ureter graft Acellular scaffolds Human 
study, 9 
patients
• Acute and chronic 
transmural 
inflammation
• Graft failure with 
aneurysmal dilation 
and thrombosis in 
complex arteriovenous 
conduits
[148]
Human 
(allograft)
Trachea Patient epithelial 
and MSC derived 
chondrocyte
Human 
study
• Immediate functional 
airway
• No immunogenic 
reaction
[149]
Table 1. 
Various decellularized xeno derived organs that are used in in vitro, animal and human studies.
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antibodies to inhibit immune rejection; these include Galα1-3Galβ1-4GlcNAc 
(referred to as α1,3Gal), Hanganuziu-Deicher (H-D) antigen, Tn, Forssman anti-
gen, Sda antigen, etc. [39, 40]. Two antibody-mediated processes are hyperacute 
rejection (HAR) and acute humoral xenograft rejection (AHXR), which attack 
mainly the vascular system of graft tissue. HAR is mediated by natural antibodies 
against α-1,3Gal epitope, present in vascular endothelium of mammals except for 
humans, or their most recent ancestors, the Old World monkeys [31, 41]. α-1,3Gal 
epitope is expressed in other organisms, because of increased human interac-
tion with these animals; anti α1,3Gal is being developed in human sera. When it 
binds to its antigen determinant site of anti α1, 3Gal, it activates the complement 
system and coagulation system to reject the graft within minutes to hours. HAR is 
histologically characterized by the presence of interstitial hemorrhage edema and 
thrombosis in small blood vessels. The depletion of α1,3Gal antibody or comple-
ment inhibition may be the best strategies to prevent HAR. But early attempts to 
reduce antibody by injecting a competitive antagonist of α1,3Gal antigen were 
unsuccessful [42] because AHXR can reject graft with a very low concentration 
of α1,3Gal antibody after several days or weeks. On the other hand, non-alpha 
Gal antigens Hanganuziu-Deicher (H-D) antigen and Sda antigen are present in 
vascular endothelium and on the surface of erythrocyte of all mammals except 
humans. The antibody against these H-D and Sda antigens is responsible for HAR 
and AHXR reaction via activation of complement (classical pathway) and coagula-
tion system in α1,3Gal transferase gene knockout (GalT-KO) pigs [40, 43, 44]. The 
complement can also be activated via alternative pathway by islets transplantation 
and cause instant blood-mediated inflammatory reaction (IBMIR), resulting in an 
early rejection of transplanted islets [45]. The most successful approach to prevent 
antibody-mediated xenograft rejection is (i) transgenic pigs that express human 
complement regulatory protein that inhibits antibody-mediated complement 
activation [46] and (ii) pigs with a knockout α1,3Gal transferase gene [47, 48]. The 
elimination of α1,3Gal epitope extended the survival of xenograft to 2–6 months 
[43]. On the other hand, combination of both strategies at a time has increased the 
graft survival. Recently significant prolongation of graft survival was documented 
more than 900 days in a pig-to-baboon cardiac xenograft from α1,3Gal transferase 
knockout, which express human complement regulatory protein CD46 and human 
thrombomodulin (GTKO.hCD46.hTBM) [49, 50]. The strength of cellular rejection 
of xenotransplantation remains uncertain, because of difficulty in avoiding HAR 
and AHXR.
Xenografts are more prone to rejection when compared to allografts due to the 
antibodies produced by T-cells dependent activated B-cells. Inclusion of T-cell sup-
pressive treatment significantly prolonged the survival rate (>400 days) of xeno-
graft, where natural antibody-mediated immune rejection was suppressed [49–51]. 
The initial immune reaction by HAR and AHXR produced pathogen-associated 
molecular patterns (PAMPs) which activate the innate immune system, such as NK 
cells, macrophages, and neutrophils. Overcoming these barriers needs severe and 
sustained exposure to immune-suppressive drugs, which is very much harmful to 
host tissue.
All biologists are focusing on cells and intracellular contents and their regulation 
to escape from immune reaction, but the scenario has changed after Hauschka and 
Konigsberg’s work in 1966 [52]. It was reported that only the ECM can differenti-
ate myoblast to myotube formation. As the ECM has inbuilt tissue-specific matrix 
composition and topological cues, it may be an ideal scaffold for the use in tissue 
engineering. Both antibody-mediated and innate immune responses trigger by the 
specific receptor present on their respective target cells and inflammatory mol-
ecules like TNF, IFN, and different cytokines released upon activation of specific 
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cells. Decellularization is the best strategies to evade immune reaction by removing 
cells as well as receptors present on their surface membrane. Unfortunately, the 
implantation of decellularized allograft into a human produced the mixed type of 
result of compatibility and recipient immune response. In spite of all the hurdles, 
some early clinical success of ECM scaffold was achieved [53, 54], but a low level of 
immune reaction was identified by some group. The heart and lung xenotransplan-
tation working group in the National Heart, Lung, and Blood Institute (NHLBI) 
has identified xenogeneic immune response against ECM to be a major problem to 
use in clinical medicine [55]. Cryopreserved human allografts are extensively used 
in cardiac valve reconstruction; immunologic response of these allografts has been 
investigated by several groups to activate the anti-HLA antibody. Hawkins et al. 
reported that HLA class I and II antigens reduced by 99% in the decellularized 
human allograft, and postoperation reactive antibody levels of HLA class I or II did 
not increase in children up to 12 months [56]. The inhibition of the immunomodu-
latory effect of decellularized tissue is obtained mainly by the removal of predomi-
nantly alpha-gal epitope along with other non-gal antigen in vascular endothelium 
and by removal of MHC class I and II molecules during decellularization. Although 
the donor-derived MHC class I became undetectable at the time of decellulariza-
tion, it again reached measurable value following implantation (host-derived MHC 
class I) and is vascularized with host tissue [57, 58]. The underlying mechanism 
of decellularization on host immune response remains to be determined. Due to 
low or zero levels of MHC class I and II, T-cell proliferative response as well as 
B-cell activation is inhibited, and the anti-inflammatory effect can be seen in vitro, 
which results in the reduction of IL-2 and IFN-γ as well. As there is no MHC class 
antigen-presenting receptor, T cell does not recognize the foreign antigen, and 
T-cell-mediated immune response is suppressed. But the elevation of IL-10 fails to 
conclude the underlying mechanism because it has the only source from activated 
T cell, B cell, and macrophages [58]. It is reported that M2 phenotype in the graft 
prevents rejection of the xenogeneic donor tissue; however, the mechanism of 
macrophage activation to release IL-10 remains unknown. Till now, it is not well 
understood which protein and in which way decellularized xenogeneic material 
promotes immune reaction. The decellularized tissue may expose new protein, and 
the decellularization protocol may also have a significant impact on the response of 
human mononuclear cells [59]. Rieder et al. [60] reported that decellularized vascu-
lar wall elicited more immune cell proliferation than native equivalent, and hence, 
it proved the above hypothesis. It also hypothesized that opsonization would be the 
way of inflammation response and can occur through preformed antibody or bind-
ing of unspecific plasma protein to the surface. In genetically modified organism, 
(pig) alpha-gal epitope is knocked out, and it does not elicit immune response in 
decellularized tissue, but in unmodified xenogeneic tissue, some amount of alpha-
gal antigen may be retained, and that could be enough to stimulate immunogenic 
response. However, further study is needed to find out the mechanism of immune 
response with regard to decellularized matrices.
2.1 Strategies to resolve immune reaction against xenogeneic DECM
Xenogeneic dECM has a huge potential to be used in tissue engineering and 
regenerative medicine; some early enthusiastic studies in animal and clinical tri-
als using decellularized tissues resulted in severe inflammatory reaction, fibrous 
overgrowth, and tissue destruction [61–64]. Despite all these immunological reac-
tions, in recent years xenogeneic biomaterials are being used in abdominal surgery 
[65–67]. There have been some early studies, where glutaraldehyde cross-linking in 
native matrix inhibits immune response by the modification of surface area of tissues 
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that inhibit the interaction with peripheral blood mononuclear cell (PBMC) and in 
turn T-cell activation [68]. But the problem of glutaraldehyde fixation is that it can 
change the tissues’ topology and promote their degradation by calcification [69]. The 
natural cross-linking product quercetin, a plant flavonoid pigment, may be more 
effective, which increases mechanical strength and reduces immunogenicity [70].
3. Importance of xenografts in dECM-based bioprinting
Organs in the human body are extremely complex structures consisting of 
multiple cell types arranged in defined spatial organization, with varied ECM 
composition. It is due to this balanced and organized compositions that organs 
achieve perfect functionality [71]. Any disruption to this native structure alters the 
functionality of the organ drastically. The demand for organ transplantation is 
increasing exponentially due to the rise in traumatic injuries and changes in lifestyle, 
while the supply of organs increased marginally over time. The demand for organ 
transplantation is estimated to further rise with the advancements in diagnostics 
leading to early detection of diseases [72]. Researchers all over the world have been 
striving hard to find alternative strategies to reduce this gap for many years, using a 
combination of many materials along with cells [73]. As a result, researchers devel-
oped comparatively simple organs using tissue engineering approaches, such as 
artificial skin [74], cartilage [75], and trachea [76] that display a part or nearly full 
functionality of the particular tissue. Xenotransplantation is another promising 
approach that was started in early 1920s and has a potential to serve as a temporary 
measure to save patient’s life in the absence of allogenic organ [77]. Nevertheless, the 
barriers such as graft failure due to immune reaction [63] and infections from the 
graft to the patient prevent the acceptance of xenotransplantation as a treatment 
option. Consequently, an emerging technique, 3D bioprinting, revolutionized the 
field of tissue engineering and regenerative medicine exhibiting its potential to 
develop complicated organs [78]. To fabricate a scaffold, this technique uses materi-
als that are biocompatible and cells that are tissue-specific, while the best biomaterial 
to develop a tissue that eventually goes to human body is the material derived from 
that specific tissue, viz., ECM, as it can provide reseeded cells with local tissue 
environment [23]. This property of tissue-derived material can anchor cells and 
provides sufficient biochemical and mechanical cues allowing them to proliferate 
and differentiate to those tissue-specific lineages which ultimately aid in complex 
tissue formation [79, 80]. Ideally, autologous tissues are expected not to illicit an 
immune response after implantation, thus reducing the chance of organ rejection. 
However, due to the lack of sufficient autologous tissue, allogeneic tissues are chosen 
for transplantation. Allogeneic tissues also suffer from rejection from the host due to 
antibody-mediated rejection or T-cell movement into the allograft [81]. Genetic 
dissimilarity between donor and recipient turns out to be the main cause to induce 
immune response and eventually rejection of the graft [81]. Hence, the process of 
decellularization when applied on allogeneic tissues reduces the amount of genetic 
material, thereby allowing graft survival in the host [82]. But, the final yield of 
material after all the processing of tissue is very low and is insufficient for printing a 
higher volume 3D structure. Because of which, considering patient’s own tissue or 
tissue from the same species for development of bioink is not practical. The very next 
alternative that researchers explored was to obtain tissue source from other species 
and use its matrix as a bioink for tissue development [23]. The concept of using other 
species (porcine) tissue as a source of material for humans emerged due to the 
anatomical and physiological similarities between both the species [83, 84]. Apart 
from the cellular content, organs are rich in the noncellular component, i.e., 
9Tissue-Specific Bioink from Xenogeneic Sources for 3D Bioprinting of Tissue Constructs
DOI: http://dx.doi.org/10.5772/intechopen.89695
ECM [85]. In almost all the tissues, ECM proteins are produced by the resident cells 
[85, 86]. Many macrolevel molecules, growth factors, and fibrillar proteins in varied 
quantities constitute this considerable volume of the tissue [85]. Polysaccharides and 
proteins such as glycosaminoglycans (GAGs), hyaluronan, collagen, fibronectin, 
laminin, and elastin are the major ECM components in an organ [85]. These ECM 
components allow cell adhesion and cell migration, provide biochemical and 
mechanical properties, and impart elasticity that helps cells to obtain morphological 
orientation and physiological functionalities. Of all the ECM components men-
tioned, collagen is the most abundant protein which almost covers 30% of the 
protein content present in multicellular organisms [85, 86]. In vertebrates, as many 
as 28 different types of collagen are recognized with 46 distinct polypeptide chains, 
and the sources of collagen are abundantly available from marine animals to animals 
that live on land [87]. The main role of this profoundly available protein is to provide 
mechanical strength, maintain cellular adhesion, and support migration and other 
cellular functionalities that direct mature tissue formation [85]. To develop tissues 
like bone [88], skin substitutes [89], small intestine tissue [90], skeletal muscle 
tissue [91], collagen that is extracted from xenogeneic sources has been used exten-
sively in research works. Elastin is another ECM component that connects with 
collagen to provide elasticity to the tissue. It is due to this close association; elastic 
nature of tissue is being maintained. To develop constructs in vitro, along with the 
exposing cells to abundant proteins, enough mechanical properties are to be pro-
vided [85]. Hence, it is necessary to include elastin components into the engineered 
scaffold which imparts mechanical properties to the tissue. By combining the 
proteins, viz., different types of collagen and elastin, a reasonable amount of work 
has been done on blood vessel engineering, heart valve development, tissue-engi-
neered vascular grafts, musculoskeletal tissues, cartilage, and skin engineering [92]. 
The other fibrous protein that contributes for organization of ECM and is respon-
sible for cell functionality such as cellular attachment is fibronectin. Scaffolds that 
are functionalized with fibronectin enhanced properties such as cell adhesion [93, 
94], promoting elastin deposition [95]; cellular migration responsible for tumor 
metastasis [96, 97] has been reported in literature. When it comes to engineering a 
tissue in vitro using 3D bioprinting, the material should be biocompatible as well as 
print friendly. Components of ECM such as collagen, elastin, and fibrin were 
explored for them to be used as bioinks either separately or in combination with one 
another in 3D bioprinting technology. The potential of collagen as bioink was 
displayed for developing human skin model with keratinocytes and fibroblasts [98], 
cartilage tissue engineering [99], 3D collagen-based cell blocks that exhibited 
osteogenic activity [100], and osteochondral mimicking structures [101] and in bone 
regeneration applications [102]. The use of fibrinogen as a bioink was also reported 
for developing cartilage [103, 104] and vascular grafts [105]. The immune response 
to xenogeneic collagen in human models was reported to be not adverse, and in most 
of the cases, the presence of antibodies for xeno-derived collagen was due to by-
products during acceptance of implanted graft by host [106]. It is also reported 
in vitro experiments conducted with collagen and elastin derived from porcine and 
bovine did not trigger immune cells nor trigger proliferation of isolated B and T cells 
[107]. Nonetheless, to mimic native tissue environment for enhanced cellular 
functionality, a combination of all the proteins and macromolecules is required. 
Hence, instead of using all the macromolecules separately in varied amounts, 
researchers started using ECM of the tissue for tissue engineering and 3D bioprint-
ing applications (Figure 2), thereby providing all the necessary cues to the reseeded 
cells in essential amounts. For better acceptance of the 3D printed structure with 
ECM, decellularization of animal tissue is done to remove the maximum cellular 
content prior to 3D printing process. This reduces the chances of xenogeneic 
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rejection in human body. In the next section, the use of dECM as a bioink for 3D 
printing applications is discussed.
4. Current status of the xenografts application in bioprinting
The process of decellularization dates to 2000s, wherein organs such as skin, 
vascular tissue, and bladder were decellularized. In 2014, it was first shown that 
after decellularization process, the ECM that is devoid of cellular material could 
be used as a bioink for 3D printing applications [23]. In the recent past, almost 
all the organs have been subjected to the process of decellularization and used for 
3D bioprinting. With 3D bioprinting of decellularized organs such as the heart, 
liver, cartilage, adipose tissue, skeletal muscle, skin, etc., researchers have demon-
strated the potential of dECM-based constructs in terms of cell compatibility, cell 
Figure 2. 
Schematic representing the process of 3D bioprinting, in vitro maturation and transplantation of tissues 
developed from animal tissue derived decellularized extracellular matrix.
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attachment, migration, and proliferation. Decellularized heart matrix derived from 
porcine showed an enhanced expression of myosin heavy chain [23] and expression 
of transcription factors by cardiac progenitor cells [108]. The functionality of 3D 
engineered heart, developed from decellularized rat heart, was also demonstrated 
in one study [109]. Similarly, decellularized liver matrix from porcine exhibited 
consistent secretion of urea and albumin up to 14 days of culture [110] and higher 
levels of markers suggesting hepatocyte maturation [27]. Early adipogenic marker 
and lipoprotein lipase were notably observed in human-derived decellularized 
adipose tissue [23]. However, there is a need of further in vitro experiments on 
decellularized matrices, to completely replicate the complex geometry of the 
organs. With the current state of art, the in vitro models can be tested for immune 
response in animal models. For any biological material that is being implanted 
should contain as less as 50 ng/mg of DNA content for not eliciting the immune 
response in host body. To ensure this low level of nucleic acid content, the process 
of decellularization of xeno tissues must be stringent and harsh. Detergents such as 
SDS and Triton X served as chemical agents to remove the maximum DNA content 
from tissues in decellularization process. Using chemical treatment, acceptable level 
of DNA content was achieved in almost all the tissues decellularized so far. Apart 
from DNA nuclear material, Gal epitopes present in animals are also found to be 
responsible for acute implant rejection [23]. There are few reports from literature 
wherein 3D dECM scaffolds have been implanted in animal models to understand 
the host response. In one study, scaffolds that were fabricated using decellularized 
adipose tissue derived from porcine were implanted into mice. Due to significant 
reduction in DNA content and gal epitopes, the ECM grafts showed no signs of 
inflammation or necrosis. Also, there was formation of neo-adipose tissue with 
mature adipocytes supporting adipogenesis and acceptance of a xenograft [111]. 
Porcine-derived skin was also subjected to decellularization to show its potential 
in skin tissue engineering. Using chemical such as trypsin/EDTA and Triton X, 
the decellularized skin matrix was digested to form bioink, and a skin substitute 
was printed. This, when implanted into the wound of 10 mm in mice, accelerated 
wound healing was observed when compared to control groups. Further, immuno-
fluorescence staining showed early differentiation markers for epithelial tissue and 
CD-31 signifying re-epithelialization and vascularization, respectively [112]. The 
reported results exhibit the acceptance of xeno-derived dECM-based 3D bioprinted 
scaffolds by the host tissue. This is made possible due to the stringent chemicals and 
enzymes involved in decellularization process. Nevertheless, much more studies 
and experiments both in vitro and in vivo must be done for using these scaffolds as 
replacement of deceased parts in the human.
5. Regulatory facets of xeno dECM-based tissue transplantation
Although the prospective benefits are unquestionable, the use of xenoge-
neic products in human health care raises a number of issues; hence it has to be 
controlled strictly by the regulatory bodies to avoid complications. The duty of 
regulatory bodies is to regulate the indiscriminate use of animal-sourced material 
intended for human health application. The challenges include (1) the potential 
risk of transmission of infectious agents from source animals, (2) informed consent 
related issues, and (3) animal welfare issues [113].
From the preclinical testing, the regulations are made strict for the human 
welfare before use in clinical trials. In general, enough studies have to be performed 
for safety characterization of therapeutic agents including the efficacy or the activity 
and the toxicity or undesired effects to the host system. This type of potential clinical 
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risks constitutes an important component of an FDA regulation. Transfer of animal 
microorganisms to the recipient with the graft during xenograft transplantation is 
another major concern for regulatory authorities [114]. There are reports that HIV, 
hepatitis B and C, Creutzfeldt-Jakob disease, and rabies can be transmitted between 
humans during transplantation. It is also proved that contact between animals and 
humans during animal husbandry and from pets or food products can lead to zoo-
notic infections. So, the use of animal cells, tissues, and organs in any forms keeps 
the public health at risk with known and unknown infections. Hence it is advised to 
go for thorough screening for all kind of possible zoonotic infections by following 
the standard protocol [113]. Moreover, the risk of these microorganisms or virus 
getting adapted to human-to-human transmission is also a major factor that has to be 
considered, which might be a concern for general population [115]. When it comes to 
cross-species whole organ transplantation, there is unavoidable transfer of endog-
enous retrovirus that is existing in the genome of all porcine cells into the patient 
receiving the organ. However, there exists no documentation regarding the transfer 
of these viruses in humans who are exposed to pig organs [116], probably due to the 
lack of long-term observation.
Preclinical studies provide valuable insight into the safety issues before being 
used in the human volunteers. Animal welfare is a major concern during the appli-
cation of xenogeneic products in humans. Since animals’ welfare is a major ethical 
issue, it is considered by regulatory bodies before approving any product of animal 
origin for clinical use.
Also, during the clinical trial stages or in long term, the volunteers or the 
patients and the close contacts should be educated about the chance of infectious 
disease risks and about how to manage those risks. Moreover, such counseling 
should also be continued for long term as some infection may take years to get 
manifested. Also, lifelong surveillance is advised by FDA irrespective of the status 
of the implant or graft or other xenotransplantation product.
Conversely, 3D bioprinted in vitro organs and tissues that are being developed 
using dECM are expected not to pose potential threat to recipients. This is because 
the cell and nucleus materials are being removed from the tissue using harsh chemi-
cals during the process of decellularization. However, the regulatory bodies ensure 
that xenotransplantation is allowed only when there are evidences that show near-
zero chance of recipient getting infected and informed consent, and acceptance 
for lifelong postoperative care from the patient was collected [116]. Nevertheless, 
stringent regulations will be required from regulatory bodies to monitor the pros 
and cons for a longer duration.
6. Ethical and safety concerns
There are numerous challenges and hurdles being faced for translating xenoge-
neic products to the clinical level. Though the potential of tissue- or organ-derived 
bioink for 3D bioprinting is getting proved and accepted, to reach human level it 
must overcome ethical concerns apart from dealing with technological and regu-
latory challenges. The opinions expressed on ethics behind using xeno-derived 
material for humans are based on the source of material and the consequence after 
transplants, which are already mentioned in the regulatory facets [117]. There are 
few groups who argue that the primary idea of using animal organ into human is 
unethical, while few claiming that the detrimental outcomes after the transplant 
are unacceptable [118]. The apprehension on the outcomes of the xenotransplanta-
tion seems valid as there are reports in the literature suggesting that patients who 
received the animal organs survived only for a short span [77]. The use of animal 
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organ in patient started in the twentieth century. Organs such as liver, heart from 
baboon [119], and kidney from chimpanzee [120] were transplanted to patients who 
survived for a very short lifespan ranging from 20 to 195 days after the implantation 
[77]. Immune rejection is the primary reason for failure of the graft [77]. Apart 
from immune response from the host, there are insufficient scientific evidences 
about the risk of transmission of pathogens that are passive in animal species [117]. 
Though it is proven that these microorganisms that are existing in animal species are 
not harming them, it could be fatal when they enter other species [117]. It is ethical 
to have an informed consent from the patient, not only regarding the transplanta-
tion but also about all the further complications that could arise due to the foreign 
material being placed inside [117, 121]. With xeno-organ transplantation, the risk 
of animal virus and microorganisms entering human body is expected to rise [121]. 
Apart from this, there are a lot many unknown viruses that are hosted by animal 
species whose effects are not at all predictable [117]. Hence, the recipient should 
also be informed about the risks and preventions that he/she must take posttrans-
plantation, restricting his freedom [121, 122]. Further, to increase the success rate 
of transplants, recipients are constantly under the influence of immunosuppres-
sant drugs, which would enhance his chances of other infections [117]. However, 
immunological reactions are not reported much after using dECM 3D bioprinted 
constructs. Additionally, one has to justify whether the amount that is being spent 
on xenotransplantation research for translation to clinical level is really worth, as 
it can help a relatively smaller group of people. Furthermore, for animal welfare, 
there are animal-related ethical issues which are considered important similar to 
human ethical issues [123]. Some groups believe that, the use of animals to fulfill 
human needs is strongly unethical, while few accept that if the benefits surpass the 
degree of suffering of animals, then there is no harm to use animal organs for saving 
human life [124]. Almost all the vertebrates suffer and perceive pain in a similar way 
[121]. Producing transgenic animals for organ transplantation also received criti-
cism, as during this process, much more pain and suffering is imposed on animals 
due to multiple experiments in succession. In order to reduce the chance of viral 
transmissions, these transgenic animals are quarantined and kept in isolation [121]. 
Hence, the supports for animal welfare argue that the animals that undergo genetic 
engineering technique will be deprived of its natural habitat and are forced to live 
in a secluded place with pain and agony [117]. Will this suffering of an animal be 
the guarantee that its organ is successfully put into use remains as an unanswered 
question. Apart from ethics, religious feelings also come into play. A pig that is 
considered to have similar genetic and physiological traits similar to human [125] is 
considered unclean in many religions but is considered as a versatile model in bio-
medical research. On the other hand, if the benefits and safety of xenotransplanta-
tion is proven for human well-being, dealing with animal ethics could be vindicated. 
Nevertheless, how well the community approves and agrees to the use of transgenic 
animal organs for transplantation to serve humans is yet to be understood.
7. Future perspective
We believe that the severity of some disease conditions will be able to justify the 
use of xenogeneic therapeutic options, but the risk and benefits must be evaluated 
and concluded at the earliest. The most important concern, infectious disease trans-
mission, including the chance of latent viral infections, must be studied in a larger 
picture including all possible disease transmissions. Though studies are limited, 
severe immunological reactions are not reported by using decellularized bioinks 
till date indicating its future potential in regenerating organs and tissue. Large 
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population studies are required to rule out the possibilities of rejection. A well-
defined animal source is also required as species close to humans are not preferred. 
The animal husbandry conditions must be defined and should start dedicated farms 
isolated from other animals and be monitored regularly to avoid unexpected or 
non-listed diseases. Moreover, an unquestionable monitoring system for animal 
welfare conditions is also important during the raise in the use of xeno-products in 
human.
8. Conclusion
The tissue-derived decellularized extracellular matrice bioink is the latest trend 
in the field of 3D bioprinting. The 3D bioprinted constructs from xenogeneic dECM 
are yet to be studied and analyzed extensively. However, the immune response to 
xenogeneic collagen, the major dECM-derived bioink component, in human models 
is not induced by any complicated immune reactions in the host. Though studies 
are in progress, the 3D bioprinted constructs with xenogeneic dECM bioink are 
least studied for safety and efficacy despite immune reactivity studies. The animal 
welfare-related issue is untouched. The initial studies using xenogeneic decellular-
ized matrices are tempting; therefore it is worth to speculate that 3D bioprinting 
with xenogeneic dECM can revolutionize the field of regenerative medicine.
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